Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC).
The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI 30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m2 for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematological toxicities were mild.
Ardizzoni
A
A
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Pronzato
P
P
Repetto
L
L
De Palma
M
M
Canobbio
L
L
Gulisano
M
M
Fusco
V
V
Rosso
R
R
Ganzina
F
F
D000284:Administration, Oral; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D015255:Idarubicin